Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 6:28 PM
Ignite Modification Date:
2025-12-24 @ 6:28 PM
NCT ID:
NCT01256268
Brief Summary:
The purpose of this study is to:
* Test the safety of a new investigational drug called MK-8669 (ridaforolimus)
* Determine the maximum tolerated dose of MK-8669
* Determine the effectiveness of the maximum tolerated dose of MK-8669
Detailed Description:
This is a phase 1A/1B study. Phase 1A is designed to determine the maximal tolerated dose (MTD) and toxicity of ridaforolimus in combination with paclitaxel and carboplatin in patients with advanced or recurrent solid tumors. The MTD determined in this study will be the recommended dose to study in the phase 1B or in future phase 2 trials.
Study:
NCT01256268
Study Brief:
Protocol Section:
NCT01256268